Analysts predict that Ra Pharmctl Inc (NASDAQ:RARX) will post earnings per share of ($0.57) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Ra Pharmctl’s earnings. The company is scheduled to report its next earnings results on Thursday, August 10th.

According to Zacks, analysts expect that Ra Pharmctl will report full year earnings of ($2.25) per share for the current year, with EPS estimates ranging from ($2.35) to ($2.14). For the next fiscal year, analysts forecast that the company will report earnings of ($2.99) per share, with EPS estimates ranging from ($3.47) to ($2.50). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that follow Ra Pharmctl.

Ra Pharmctl (NASDAQ:RARX) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.08.

RARX has been the subject of a number of recent research reports. BMO Capital Markets boosted their price objective on shares of Ra Pharmctl from $24.00 to $31.00 and gave the company a “positive” rating in a research report on Tuesday, March 7th. Zacks Investment Research raised shares of Ra Pharmctl from a “sell” rating to a “hold” rating in a research report on Wednesday, April 12th. Jefferies Group LLC reissued an “in-line” rating and set a $25.00 price objective on shares of Ra Pharmctl in a research report on Tuesday, March 7th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $19.00 price objective on shares of Ra Pharmctl in a research report on Tuesday, April 18th. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $27.00.

TRADEMARK VIOLATION WARNING: This story was first posted by Financial Market News and is the sole property of of Financial Market News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.financial-market-news.com/2017/06/18/zacks-analysts-anticipate-ra-pharmctl-inc-rarx-to-announce-0-57-earnings-per-share.html.

In related news, major shareholder Bioventures Ltd Novartis sold 12,114 shares of the company’s stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $22.63, for a total value of $274,139.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 152,460 shares of company stock valued at $3,745,249 in the last ninety days.

Hedge funds and other institutional investors have recently modified their holdings of the company. American International Group Inc. purchased a new position in shares of Ra Pharmctl during the first quarter valued at $102,000. Teachers Advisors LLC purchased a new position in shares of Ra Pharmctl during the fourth quarter valued at $135,000. TIAA CREF Investment Management LLC increased its position in shares of Ra Pharmctl by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after buying an additional 3,859 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Ra Pharmctl by 151.8% in the first quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after buying an additional 5,700 shares in the last quarter. Finally, Fred Alger Management Inc. purchased a new position in shares of Ra Pharmctl during the fourth quarter valued at $223,000. 62.85% of the stock is owned by institutional investors.

Shares of Ra Pharmctl (NASDAQ RARX) traded down 0.28% during trading on Tuesday, reaching $21.30. The company’s stock had a trading volume of 179,542 shares. The firm’s 50-day moving average price is $23.17 and its 200-day moving average price is $19.70. Ra Pharmctl has a one year low of $12.05 and a one year high of $27.84. The company’s market capitalization is $480.68 million.

Ra Pharmctl Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Get a free copy of the Zacks research report on Ra Pharmctl (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.